FDA Approves Dupixent for Chronic Spontaneous Urticaria in Young Children

MONDAY, May 4, 2026 (HealthDay News) -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of children (aged 2 to 11 years) with chronic spontaneous urticaria (CSU).This approval expands the previous approval for adults and adolescents ages 12 years and older with CSU who remain symptomatic despite histamine-1 antihistamine treatment. The fully human monoclonal antibody is administered as a subcutaneous injection.Data from the LIBERTY-CUPID clinical study program informed the approval, which included efficacy and safety data from two phase 3 studies (study A and study C) in adults and adolescents aged 12 years and older with CSU, as well as pharmacokinetics data from the CUPIDKids phase 3 study in children aged 2 to 11 years with CSU. Results from study A and study C showed that Dupixent significantly reduced itch severity and urticaria activity (a composite of itch and hives) versus placebo at week 24 and also increased the likelihood of well-controlled disease or complete response versus placebo. The safety of Dupixent was supported by data from pediatric patients in other indications."Dupixent is the first biologic approved for patients as young as 2 years of age, offering a targeted approach that inhibits IL-4 and IL-13 signaling, two key and central drivers of the type 2 inflammation that contributes to this disease," Alyssa Johnsen, M.D., Ph.D., from Sanofi, the manufacturer of Dupixent, said in a statement. "Until now, these patients had to rely on limited treatment options that didn't address potential critical mediators of chronic spontaneous urticaria."More Information.Sign up for our weekly HealthDay newsletter

FDA Approves Dupixent for Chronic Spontaneous Urticaria in Young Children

Related Stories

Adenotonsillectomy Improves Sleep Efficiency in Pediatric Obstructive Sleep Apnea

Allergic Rhinitis Could Lead to Hearing Impairment in Children, Teens

First Gene Therapy for Genetic Hearing Loss Gains FDA Approval

Gut Bacteria Might Drive Rare Food Allergy in Children, Study Finds